BiotechTube

Fludarabine + Cyclophosphamide + Thymoglobulin

Phase 1Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scleroderma

Conditions

Scleroderma, Systemic Sclerosis

Trial Timeline

Jul 1, 2002 → Mar 1, 2007

NCT ID
NCT00040651

About Fludarabine + Cyclophosphamide + Thymoglobulin

Fludarabine + Cyclophosphamide + Thymoglobulin is a phase 1 stage product being developed by Amgen for Scleroderma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00040651. Target conditions include Scleroderma, Systemic Sclerosis.

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00040651Phase 1Terminated

Competing Products

15 competing products in Scleroderma

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
29
Cuprimine (penicillamine)MerckPre-clinical
26
rapcabtagene autoleucel + rituximabNovartisPhase 2
42
STI571NovartisPhase 2
35
Imatinib mesylateNovartisPhase 2
27
imatinib mesylateNovartisPhase 2
35
Mycophenolate mofetilRochePre-clinical
26
Mycophenolate mofetil + Cyclophosphamide + PlaceboRochePhase 2
35
BMS-986020Bristol Myers SquibbPhase 2
27
dasatinibBristol Myers SquibbPhase 1/2
32
Abatacept + PlaceboBristol Myers SquibbPhase 1/2
32
AVID200Bristol Myers SquibbPhase 1
29
RilonaceptRegeneron PharmaceuticalsPhase 1/2
32
Riociguat + PlaceboBayerPhase 2
32
Riociguat (Adempas, BAY63-2521) + PlaceboBayerPhase 2
32